medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial

Korean Journal of Internal Medicine 2019년 34권 5호 p.1125 ~ 1135
 ( Yhim Ho-Young ) - Chonbuk National University Medical School Department of Internal Medicine

 ( Choi Won-Il ) - Keimyung University Dongsan Medical Center Department of Internal Medicine
 ( Kim Sung-Hyun ) - Dong-A University College of Medicine Department of Internal Medicine
 ( Nam Seung-Hyun ) - Veterans Health Service Medical Center Department of Internal Medicine
 ( Kim Kyoung-Ha ) - Soonchunhyang University Seoul Hospital Department of Internal Medicine
 ( Mun Yeung-Chul ) - Ewha Womans University School of Medicine Department of Internal Medicine
 ( Oh Do-Yeun ) - CHA University School of Medicine Department of Internal Medicine
 ( Hwang Hun-Gyu ) - Soonchunhyang University Gumi Hospital Department of Internal Medicine
 ( Lee Keun-Wook ) - Seoul National University Bundang Hospital Department of Internal Medicine
 ( Song Eun-Kee ) - Chonbuk National University Medical School Department of Internal Medicine
 ( Kwon Yong-Shik ) - Keimyung University Dongsan Medical Center Department of Internal Medicine
 ( Bang Soo-Mee ) - Seoul National University Bundang Hospital Department of Internal Medicine

Abstract


Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients.

Methods: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication.

Results: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and 110 (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died.

Conclusions: Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer.

키워드

Neoplasms; Recurrence; Rivaroxaban; Venous thromboembolism; Therapeutics
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS